The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.